Phosphorus management in end-stage renal disease.
Chronic kidney disease is an important public health problem, with an increasing number of patients worldwide. One important outcome of renal failure is disordered mineral metabolism, most notably involving calcium and phosphorus balance. Of importance is that increased serum phosphorus levels are associated with increased mortality rates. Despite dietary restrictions, patients receiving dialysis invariably experience hyperphosphatemia and require treatment with phosphate binders. Existing phosphate binders are effective in reducing serum phosphorus levels, but are associated with a number of important disadvantages. Lanthanum carbonate, a new noncalcium, nonaluminum phosphate binder, represents a promising treatment for hyperphosphatemia.
Finn
William F
WF
D000085:Acetates / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism*; D002119:Calcium Carbonate / Q000627:therapeutic use; D017610:Calcium Compounds; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000378:metabolism*; D007811:Lanthanum / Q000627:therapeutic use; D010281:Parathyroid Hormone / Q000378:metabolism; D010758:Phosphorus / Q000378:metabolism*; D010760:Phosphorus Metabolism Disorders / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D011073:Polyamines / Q000627:therapeutic use; D000069603:Sevelamer; D014807:Vitamin D / Q000378:metabolism
D000085:Acetates; D017610:Calcium Compounds; D010281:Parathyroid Hormone; D011073:Polyamines; D014807:Vitamin D; D010758:Phosphorus; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer; D002119:Calcium Carbonate; D002118:Calcium; C120662:calcium acetate